← Back to headlines
Insmed (INSM) Poised for 2026 Upside with Potential $1.3B Arikayce Sales Boost
Insmed (INSM) is anticipated to see significant upside in 2026, driven by a potential $1.3 billion increase in Arikayce sales, leading Roth/MKM to initiate a 'Buy' rating.
20 Feb, 08:44 — 20 Feb, 08:44
Sources
Showing 1 of 1 sources
